ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years
Gabriela Reyes‐Castellanos
Matched on ORCID iD 0009-0002-6447-8532; OpenAlex author ID A5071408906. Sources: OpenAlex.
Their work
- Papers
- 8 (first author 3, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 23
2020: 2 papers · 2021: 2 papers · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper
Papers 8
- Adaptation of redox metabolism in drug-tolerant persister cells is a vulnerability to prevent relapse in pancreatic cancer. First author DOI 10.1038/s41389-025-00591-0↗
- Integrative study of skeletal muscle mitochondrial dysfunction in a murine pancreatic cancer-induced cachexia model. Co-author DOI 10.7554/elife.93312↗
- Combining the antianginal drug perhexiline with chemotherapy induces complete pancreatic cancer regression in vivo. Co-author DOI 10.1016/j.isci.2023.106899↗
- Pesticides and pancreatic adenocarcinoma: A transversal epidemiological, environmental and mechanistic narrative review. Co-author DOI 10.1016/j.dld.2022.08.023↗
- Pancreatic cancer intrinsic PI3Kα activity accelerates metastasis and rewires macrophage component. Co-author DOI 10.15252/emmm.202013502↗
- Targeting Redox Metabolism in Pancreatic Cancer. First author DOI 10.3390/ijms22041534↗
- Targeting Mitochondrial Complex I Overcomes Chemoresistance in High OXPHOS Pancreatic Cancer. First author DOI 10.1016/j.xcrm.2020.100143↗
- Mitochondrial Metabolism in PDAC: From Better Knowledge to New Targeting Strategies. Co-author DOI 10.3390/biomedicines8080270↗
Closest collaborators
The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Alice Carrier · 8 shared papers, 2020–2025 · strength 1.40
- Paper Adaptation of redox metabolism in drug-tolerant persister cells is a vulnerability to prevent relapse in pancreatic can… DOI 10.1038/s41389-025-00591-0↗
- Paper Integrative study of skeletal muscle mitochondrial dysfunction in a murine pancreatic cancer-induced cachexia model. DOI 10.7554/elife.93312↗
- Paper Targeting Redox Metabolism in Pancreatic Cancer. DOI 10.3390/ijms22041534↗
- Tristan Gicquel · 4 shared papers, 2020–2025 · strength 0.71
- Paper Adaptation of redox metabolism in drug-tolerant persister cells is a vulnerability to prevent relapse in pancreatic can… DOI 10.1038/s41389-025-00591-0↗
- Paper Integrative study of skeletal muscle mitochondrial dysfunction in a murine pancreatic cancer-induced cachexia model. DOI 10.7554/elife.93312↗
- Paper Combining the antianginal drug perhexiline with chemotherapy induces complete pancreatic cancer regression in vivo. DOI 10.1016/j.isci.2023.106899↗
- Nadine Abdel Hadi · 4 shared papers, 2020–2025 · strength 0.71
- Paper Adaptation of redox metabolism in drug-tolerant persister cells is a vulnerability to prevent relapse in pancreatic can… DOI 10.1038/s41389-025-00591-0↗
- Paper Targeting Redox Metabolism in Pancreatic Cancer. DOI 10.3390/ijms22041534↗
- Paper Combining the antianginal drug perhexiline with chemotherapy induces complete pancreatic cancer regression in vivo. DOI 10.1016/j.isci.2023.106899↗
- Rawand Masoud · 4 shared papers, 2020–2025 · strength 0.67
- Paper Adaptation of redox metabolism in drug-tolerant persister cells is a vulnerability to prevent relapse in pancreatic can… DOI 10.1038/s41389-025-00591-0↗
- Paper Mitochondrial Metabolism in PDAC: From Better Knowledge to New Targeting Strategies. DOI 10.3390/biomedicines8080270↗
- Paper Combining the antianginal drug perhexiline with chemotherapy induces complete pancreatic cancer regression in vivo. DOI 10.1016/j.isci.2023.106899↗
- Juan Iovanna · 3 shared papers, 2020–2025 · strength 0.48
- Paper Adaptation of redox metabolism in drug-tolerant persister cells is a vulnerability to prevent relapse in pancreatic can… DOI 10.1038/s41389-025-00591-0↗
- Paper Combining the antianginal drug perhexiline with chemotherapy induces complete pancreatic cancer regression in vivo. DOI 10.1016/j.isci.2023.106899↗
- Paper Targeting Mitochondrial Complex I Overcomes Chemoresistance in High OXPHOS Pancreatic Cancer. DOI 10.1016/j.xcrm.2020.100143↗
- Odile Gayet · 2 shared papers, 2020–2023 · strength 0.24
- Abdessamad El Kaoutari · 2 shared papers, 2020–2023 · strength 0.24
- Nelson Dusetti · 2 shared papers, 2020–2023 · strength 0.24
- Mathias Brügel · 1 shared paper, 2022 · strength 0.19
- Olivier Bouché · 1 shared paper, 2022 · strength 0.19
- Fabienne Guillaumond · 1 shared paper, 2023 · strength 0.15
- Fabrice Muscari · 1 shared paper, 2021 · strength 0.09
- Célia Cintas · 1 shared paper, 2021 · strength 0.09
- Chiara Falcomatà · 1 shared paper, 2021 · strength 0.09
- Coralie Cayron · 1 shared paper, 2021 · strength 0.09
- Céline Basset · 1 shared paper, 2021 · strength 0.09
- Romain Baer · 1 shared paper, 2021 · strength 0.09
- Benoît Thibault · 1 shared paper, 2021 · strength 0.09
- Nicole Therville · 1 shared paper, 2021 · strength 0.09
- Julie Guillermet‐Guibert · 1 shared paper, 2021 · strength 0.09
- Pierre Cordelier · 1 shared paper, 2021 · strength 0.09
- Barbara Bournet · 1 shared paper, 2021 · strength 0.09
- Dieter Saur · 1 shared paper, 2021 · strength 0.09
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.